Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Tocris Cookson Limited is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner within 1 distinct art unit. This indicates a narrow and specific focus for the company's current intellectual property efforts, likely involving a single pharmaceutical compound or biotechnological process.
The busiest examiner, DEKARSKE, MADELINE MCGUIRE, is responsible for 1 busiest examiner pending action. Since this 1 busiest examiner pending action is the only one currently pending for the company, DEKARSKE, MADELINE MCGUIRE is the primary point of contact for the entire active portfolio. The company's immediate progress in the Biotechnology & Pharmaceuticals area is therefore dependent on this single examiner's review.
With 1 pending office action and 1 distinct examiner, the administrative complexity of the portfolio is minimal. The presence of 1 distinct art unit further confirms the specialized nature of the technology currently under review. Because there is only 1 action, the company does not have the opportunity to compare DEKARSKE, MADELINE MCGUIRE's performance against other examiners in the same or different units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DEKARSKE, MADELINE MCGUIRE | 1 | 20.0% | +50.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18686693 | METHOD FOR STAINING MITOCHONDRIA | DEKARSKE, MADELINE MCGUIRE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18686693 | METHOD FOR STAINING MITOCHONDRIA | DEKARSKE, MADELINE MCGUIRE | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18686693 | METHOD FOR STAINING MITOCHONDRIA | DEKARSKE, MADELINE MCGUIRE | 1634 | §103DP | Non-Final OA | — | Pending | Feb 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTocris Cookson Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Madeline Mcguire Dekarske has the most, with 1 of Tocris Cookson Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
